| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Multiple targets involved in myocardial function, oxidative stress, and inflammatory signaling pathways (NF-κB, MAPK).
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Danshenxinkun A has been studied for its ability to improve myocardial function, reduce oxidative stress, and modulate signaling pathways such as NF-κB and MAPK. The compound is a naturally occurring compound found in Danshen (Salvia miltiorrhiza), a traditional Chinese medicinal herb used for the treatment of cardiovascular diseases. Danshenxinkun A contributes to the therapeutic efficacy of Danshen in treating heart disease, ischemia, and vascular inflammation. The compound's antioxidant and anti-inflammatory properties are likely mediated through the modulation of NF-κB and MAPK signaling pathways.
|
| ln Vivo |
In vivo studies on Danshenxinkun A are limited, as the compound is primarily studied as a component of Danshen extracts rather than as a single therapeutic agent. The compound's ability to improve myocardial function, reduce oxidative stress, and modulate inflammatory signaling suggests potential applications in the treatment of cardiovascular diseases, including heart disease, ischemia, and vascular inflammation. Danshenxinkun A, together with other Danshen components, may intervene in thrombotic diseases by adjusting targets involved in various pathways. Further studies are needed to assess the compound's pharmacokinetic properties and efficacy as a single agent.
|
| Enzyme Assay |
For mechanistic studies, in vitro assays are performed using cardiomyocytes, endothelial cells, or other relevant cell lines. Cells are treated with Danshenxinkun A at various concentrations, and oxidative stress is assessed by measuring ROS levels using fluorescent probes, or by measuring antioxidant enzyme activities (SOD, CAT, GSH-Px). NF-κB and MAPK signaling are assessed by Western blotting for phosphorylated proteins (p65, IκBα, ERK, JNK, p38). Myocardial function is assessed using cardiomyocyte contraction assays or by measuring markers of cardiac injury (e.g., LDH release).
|
| Cell Assay |
Cellular assays for Danshenxinkun A typically involve culturing cardiomyocytes, endothelial cells, or other relevant cell lines and treating them with the compound at various concentrations. Cell viability is assessed using MTT or CellTiter-Glo assays. Oxidative stress is assessed by measuring ROS levels using fluorescent probes, or by measuring antioxidant enzyme activities. Inflammatory responses are assessed by measuring cytokine production (TNF-α, IL-1β, IL-6) by ELISA. NF-κB and MAPK signaling are assessed by Western blotting for phosphorylated proteins. Myocardial function is assessed using cardiomyocyte contraction assays or by measuring markers of cardiac injury. Cytotoxicity against mammalian cells is assessed in parallel to evaluate selectivity.
|
| Animal Protocol |
In vivo efficacy of Danshenxinkun A is evaluated in animal models of cardiovascular diseases. For myocardial ischemia studies, mouse or rat models of myocardial infarction or ischemia-reperfusion injury are used, and animals are treated with Danshenxinkun A via oral or intraperitoneal administration. Myocardial function is assessed by echocardiography, and infarct size is measured by histochemical staining. Oxidative stress and inflammation in cardiac tissues are assessed by measuring malondialdehyde, glutathione, and cytokine levels. Histopathological examination of cardiac tissues is performed to assess tissue damage and inflammatory cell infiltration. Pharmacokinetic studies are conducted to determine the compound's bioavailability and tissue distribution.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Danshenxinkun A have been studied in the context of its use as a natural product. The compound has a molecular weight of 296.32 and the molecular formula C18H16O4. Key PK parameters including half-life, clearance, volume of distribution, and bioavailability are determined using LC-MS/MS analysis of plasma and tissue samples following administration. The compound's ability to reach the heart and other target tissues is important for its efficacy in cardiovascular studies. The compound should be stored at 2-8°C for long-term stability.
|
| Toxicity/Toxicokinetics |
Toxicological evaluation of Danshenxinkun A is limited, as the compound is primarily studied as a component of Danshen, a traditional Chinese medicinal herb with a long history of use. Danshen is generally considered safe for use at recommended doses, though comprehensive toxicology data for Danshenxinkun A as a single agent may be limited. Standard toxicology assessments for pharmaceutical applications would include in vitro cytotoxicity assays, acute and repeated-dose toxicity studies, and evaluation of effects on liver and kidney function. The compound's natural origin and traditional use suggest a potential favorable safety profile.
|
| References | |
| Additional Infomation |
New Kun A of Salvia miltiorrhiza has been reported in Salvia miltiorrhiza and its varieties. Data are available for Salvia miltiorrhiza and Salvia przewalskii.
Danshenxinkun A is a naturally occurring compound found in Danshen (Salvia miltiorrhiza), a traditional Chinese medicinal herb used for the treatment of cardiovascular diseases. The compound has been studied for its ability to improve myocardial function, reduce oxidative stress, and modulate signaling pathways such as NF-κB and MAPK. Danshenxinkun A contributes to the therapeutic efficacy of Danshen in treating heart disease, ischemia, and vascular inflammation. The compound is not approved as a drug and is intended for laboratory research purposes only. Its primary applications are in natural product research and the study of cardiovascular pharmacology. |
| Molecular Formula |
C18H16O4
|
|---|---|
| Molecular Weight |
296.322
|
| Exact Mass |
296.104
|
| Elemental Analysis |
C, 72.96; H, 5.44; O, 21.60
|
| CAS # |
65907-75-7
|
| PubChem CID |
149138
|
| Appearance |
Light yellow to orange solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
527.7±50.0 °C at 760 mmHg
|
| Flash Point |
287.0±26.6 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.692
|
| LogP |
3.11
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
22
|
| Complexity |
521
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cc1cccc2c1ccc3c2C(=O)C(=C(C3=O)C(C)CO)O
|
| InChi Key |
GRGPQNRHXNRJFL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H16O4/c1-9-4-3-5-12-11(9)6-7-13-15(12)18(22)17(21)14(16(13)20)10(2)8-19/h3-7,10,19-20H,8H2,1-2H3
|
| Chemical Name |
1-hydroxy-2-(1-hydroxypropan-2-yl)-8-methylphenanthrene-3,4-dione
|
| Synonyms |
Danshenxinkun A
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3747 mL | 16.8737 mL | 33.7473 mL | |
| 5 mM | 0.6749 mL | 3.3747 mL | 6.7495 mL | |
| 10 mM | 0.3375 mL | 1.6874 mL | 3.3747 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
